Business
Eckert & Ziegler Enters Partnership with Thor Medical to Enable Access of Lead-212 for the Pharmaceutical Industry
Eckert & Ziegler Enters Partnership with Thor Medical to Enable Access of Lead-212 for the Pharmaceutical
About this update from Eckert & Ziegler Se
[{"type":"text","content":"\n\n\nEQS-News: Eckert & Ziegler SE\n\n\n / Key word(s): Agreement/Alliance\n\n\n\n\n\nEckert & Ziegler Enters Partnership with Thor Medical to Enable Access of Lead-212 for the Pharmaceutical Industry \n\n\n\n\n\n\n28.05.2026 / 07:02 CET/CEST\n\n\n\nThe issuer is solely responsible for the content of this announcement.Berlin, Germany and Oslo, Norway, 28 May 2026. Eckert & Ziegler SE (ISIN DE0005659700), a world-leading specialist in isotope-related components, equipment and services for nuclear medicine and radiation therapy, today signed a collaboration and supply agreement with Thor Medical, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment. The partnership will accelerate the development of lead-212 (Pb-212) based therapies by strengthening the supply and manufacturing base for the isotope, thereby supporting the growing number of biotech and pharmaceutical companies developing lead-212 based therapies.\nDue to its favorable in-body chemistry, rapid clearance profile and suitability for theranostic applications, lead-212 has emerged as one of the most promising isotopes in targeted alpha therapy. Under the terms of the agreement, Thor Medical will initially supply lead-212 to Eckert & Ziegler for preclinical research and development. Both companies will also explore how to further integrate their complementary capabilities in isotope production and radiopharmaceutical manufacturing, with the aim of scaling up production capacity over time.\n“Eckert & Ziegler has proven itself as a reliable enabler for the radiopharmaceutical industry. When an isotope like lead-212 has the potential to open up new therapeutic avenues, we are taking responsibility in this area. Thor Medical has quietly built a leading technology platform and strong production capabilities for high-purity medical isotopes and precursor materials, making the company a strong strategic fit. We look forward to further strengthening our position as an integrated radiopharmaceutical one-stop-shop through this collaboration”, said Dr. Harald Hasselmann, Chief Executive Officer of Eckert & Ziegler SE.\nEckert & Ziegler combines radioisotope supply with fully integrated radiopharmaceutical research, development and manufacturing services. Their GMP-compliant CDMO services bridge the gap for biotech...